Skip To Main Content
Mark Deming on Muck Rack

Mark Deming

Verified
  • Staff Writer and Assistant Editor, Xperi
Michigan
As seen in: Yahoo Entertainment, Sports Illustrated, Foreign Policy Magazine, AllMusic, Yahoo, Law360, JD Supra, The National Law Review, Idaho Statesman, IP Watchdog and
I write about music and movies for a living, and I know even more useless information than YOU do.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Mark

Contact Mark, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

How Pfizer Won Fed. Circ. Patent Dispute By 1 Carbon Atom

|
By Mark Deming Verified, Chad Landmon
| Law360 Verified
By Mark Deming and Chad Landmon ( July 14, 2026, 4:57 PM EDT) -- In a precedential June 23 decision in Enanta Pharmaceuticals Inc. v. Pfizer Inc.,[1] the U.S. Court of Appeals for the Federal Circuit held that Enanta's asserted Paxlovid-related claims could not rely on a provisional application that disclosed a C2-C12 alkyl substituent but not the later-claimed C1-C12 variant.... Law360 is on it, so you are, too.
Open in Who Shared View Duplicates (208) Issue with article?

Federal Circuit Affirms Nuedexta® Injunction but Vacates Zero-Dollar Bond

|
By Corey Casey, Mark Deming Verified
| JD Supra
In Otsuka America Pharmaceutical, Inc. v. Hetero Labs Ltd.,1 the Federal Circuit affirmed a preliminary injunction blocking Hetero’s generic for Nuedexta®, upholding the construction of a dose-ratio limitation, whereby the ratio is measured by the salt forms of the drugs as administered, but vacated the district court’s waiver of an injunction bond, holding that a generic barred from launching must be given security for the sales it stands to lose.
Open in Who Shared Issue with article?

Supreme Court Hands Generics a Unanimous Win on Skinny Labels in Hikma v. Amarin

|
By Corey Casey, Mark Deming Verified
| JD Supra
A unanimous Supreme Court reversed the Federal Circuit and held that Amarin did not plausibly allege that Hikma’s skinny label and marketing actively induced infringement of Vascepa’s cardiovascular-use patents — a decisive win for the generic industry that affirms skinny labeling as a shield against method-of-use liability. Key Takeaways A decisive win for the generic industry.
Open in Who Shared Issue with article?
See all 397 licensed articles (398 Total)